CLARK IAN T 4

What Happened
Director Ian T. Clark received equity awards from Kyverna Therapeutics on May 27, 2026. The Form 4 shows a grant of 5,093 restricted stock units (RSUs) and a grant of a derivative award covering 20,582 shares (an option-like award). Both awards are reported at a $0.00 acquisition price on the Form 4 (i.e., they were granted, not purchased or sold).

Key Details

• Transaction date: 2026-05-27; Form 4 filed 2026-05-29 (timely filing).
• Reported amounts: 5,093 RSUs (non-derivative) and 20,582 derivative shares (option award) at $0.00.
• Vesting/exercise: Both awards vest in full on the earlier of (i) May 27, 2027, or (ii) immediately prior to the issuer’s 2027 annual meeting of stockholders, subject to continuous service (see footnotes F1 and F2). The derivative award will be fully vested and exercisable on the same schedule.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Presented as timely (filed two days after the transaction date).
• Transaction code: A = Award/Grant.

Context
These transactions are grants of compensatory equity (one RSU grant and one option-style award) to a company director; they are not open-market purchases or sales. Such awards are common for director compensation and do not by themselves indicate immediate buying or selling of shares. The derivative award will need to be exercised (if it is an option) after vesting for the director to convert it into common shares.